Oxford BioDynamics (LON:OBD) Shares Up 33.3% – Should You Buy?

Oxford BioDynamics Plc (LON:OBD) rose 33.3% during trading on Thursday . The stock traded as high as GBX 0.14 and last traded at GBX 0.14. 29,704,521 shares changed hands during mid-day trading, an increase of 74% from the average session volume of 17,032,373 shares. The stock had previously closed at GBX 0.10.

Oxford BioDynamics Price Performance

The company has a market capitalization of £5.58 million, a price-to-earnings ratio of -0.65 and a beta of 0.42. The stock’s 50-day simple moving average is GBX 0.16 and its two-hundred day simple moving average is GBX 0.21. The company has a quick ratio of 2.80, a current ratio of 2.01 and a debt-to-equity ratio of 131.61.

Oxford BioDynamics (LON:OBD) last posted its quarterly earnings data on Tuesday, June 30th. The biotechnology company reported GBX (0.10) earnings per share (EPS) for the quarter. Oxford BioDynamics had a negative return on equity of 451.74% and a negative net margin of 825.61%.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.